DEF 14A: Windtree Therapeutics Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance

Windtree Therapeutics is asking stockholders to approve a reverse stock split to increase its stock price and meet Nasdaq's continued listing requirements.

Summary

• Windtree Therapeutics is holding a special meeting of stockholders on April 10, 2024, to vote on two proposals.
• The first proposal is to approve an amendment to the company's charter to effect a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-25, with the specific ratio and timing to be determined by the Board of Directors.
• The second proposal is to approve the adjournment of the special meeting if there are insufficient votes to approve the reverse stock split or to establish a quorum.
• The Board of Directors believes that a reverse stock split is necessary to increase the company's stock price, meet Nasdaq's continued listing requirements, appeal to a broader range of investors, and improve the perception of the company's stock as an investment security.
• The company received a deficiency letter from Nasdaq on January 22, 2024, because its stock price fell below $1.00 per share for 31 consecutive business days.
• Windtree has until July 22, 2024, to regain compliance.
• As of February 20, 2024, there were 9,181,011 shares of common stock outstanding.
• A quorum for the special meeting requires the presence of at least 3,060,337 shares of common stock.
• The company has engaged Morrow Sodali LLC to assist with the solicitation of proxies for an estimated fee of $9,500, plus expenses.
• The Board unanimously recommends voting FOR both proposals.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting the facts of the proposed reverse stock split. While the company is facing a challenge with its stock price, the reverse stock split is a potential solution. The sentiment is slightly positive as the company is taking action to address the issue.

Positives

• A successful reverse stock split could increase the stock price, helping Windtree regain compliance with Nasdaq listing requirements.
• A higher stock price may attract a broader range of investors, including institutional investors.
• The reverse stock split will increase the number of authorized but unissued shares, providing flexibility for future financing and acquisitions.
• The Board of Directors believes the benefits of the reverse stock split outweigh the risks.

Negatives

• The reverse stock split may not increase the stock price over the long term.
• The reverse stock split could decrease the liquidity of the company's common stock.
• Some stockholders may end up owning odd lots of shares, which can be more difficult to sell.
• The reverse stock split may lead to a decrease in the company's overall market capitalization.
• The company received a Nasdaq deficiency letter on January 22, 2024, because its stock price fell below $1.00 per share for 31 consecutive business days.

Risks

• The reverse stock split may not be effective in increasing the stock price or maintaining compliance with Nasdaq listing requirements.
• The market price of the company's common stock may be affected by factors unrelated to the reverse stock split, such as business and financial performance.
• Reduced trading volume and a smaller number of market makers could result from the reverse stock split.
• The reverse stock split could be viewed negatively by the market, leading to a decrease in market capitalization.
• The company has until July 22, 2024, to regain compliance with Nasdaq listing rules.

Future Outlook

The company intends to request a second 180-day period to regain compliance with Nasdaq listing rules if it does not regain compliance by July 22, 2024. The Board has the authority to abandon the reverse stock split at any time before July 31, 2024, if it determines that such action is in the best interests of the company and its stockholders.

Management Comments

• Craig E. Fraser, Chairman of the Board, President and Chief Executive Officer, encourages stockholders to vote as soon as possible.
• The Board believes that effecting the Reverse Split would increase the price of our Common Stock which would, among other things, help us to meet certain continued listing requirements of the Nasdaq Capital Market; appeal to a broader range of investors to generate greater interest in the Company; and improve perception of our Common Stock as an investment security.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. Many companies in the biotechnology and pharmaceutical industries, which can be subject to volatile stock performance based on clinical trial results and regulatory approvals, have used reverse stock splits to maintain their listing.

Comparison to Industry Standards

• Many companies facing similar situations, such as delisting warnings from Nasdaq or NYSE, have implemented reverse stock splits.
• For example, companies like BioDelivery Sciences International and Titan Pharmaceuticals have previously used reverse stock splits to regain compliance with Nasdaq listing requirements.
• The success of a reverse stock split in maintaining compliance and improving investor perception varies depending on the company's underlying fundamentals and market conditions.

Stakeholder Impact

• Shareholders will be impacted by the reverse stock split, potentially seeing a change in the number of shares they own and the price per share.
• Employees may be affected by the company's ability to maintain its Nasdaq listing, which could impact morale and stock options.
• The company's ability to raise capital and fund its operations could be affected by its stock price and listing status.

Next Steps

• Stockholders will vote on the reverse stock split proposal at the Special Meeting on April 10, 2024.
• If approved, the Board of Directors will determine the specific reverse stock split ratio and timing.
• The company will file a Certificate of Amendment to the Charter with the Secretary of State of the State of Delaware.
• The company will monitor its stock price to ensure compliance with Nasdaq listing requirements.

Key Dates

Keywords

reverse stock split, proxy statement, stockholders meeting, Nasdaq, common stock, Windtree Therapeutics, listing requirements, WINT